Richard Gelber
机构: Professor, Harvard Medical School, Harvard TH Chan School of Public Health, Dana-Farber Cancer Institute, Frontier Science Foundation
每年引用次数
引用次数
引用: 123,984
H-指数: 154
I10-指数 : 496
出版物: 861
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A Francis , Olivia Pagani , Gini F Fleming , Barbara A Walley
The New England Journal of Medicine 379 ( 2) 122 -137
177
2018
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
Steven E Lipshultz , Nader Rifai , Virginia M Dalton , Donna E Levy
The New England Journal of Medicine 351 ( 2) 145 -153
689
2004
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine J. Piccart-Gebhart , Marion Procter , Brian Leyland-Jones , Aron Goldhirsch
The New England Journal of Medicine 353 ( 16) 1659 -1672
6,196
2005
Ophthalmic Evaluation of Survivors of Acute Lymphoblastibc Leukemia
Darren L. Hoover , Lois E.H. Smith , Stewart J. Turner , Richard D. Gelber
Ophthalmology 95 ( 2) 151 -155
30
1988
Tailoring treatments for the individual patient
Richard D. Gelber , Marco Bonetti , Aron Goldhirsch
The Breast 12
1
2003
Problems with the progesterone receptor in practice
V. Craig Jordan , Richard D. Gelber
Journal of Clinical Oncology 25 ( 15) 1957 -1959
6
2007
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer : predictive value of centrally reviewed expression of estrogen and progesterone receptors, international breast cancer study group
Giuseppe Viale , Meredith M. Regan , Eugenio Maiorano , Mauro G. Mastropasqua
Journal of Clinical Oncology 26 ( 9) 1404 -1410
88
2008
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Henning Mouridsen , Aparna Keshaviah , Alan S. Coates , Manuela Rabaglio
Journal of Clinical Oncology 25 ( 36) 5715 -5722
147
2007
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Giuseppe Viale , Meredith M. Regan , Eugenio Maiorano , Mauro G. Mastropasqua
Journal of Clinical Oncology 25 ( 25) 3846 -3852
336
2007
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Diana Crivellari , Zhuoxin Sun , Alan S. Coates , Karen N. Price
Journal of Clinical Oncology 26 ( 12) 1972 -1979
111
2008
Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials
Bernhard C. Pestalozzi , David Zahrieh , Elizabeth Mallon , Barry A. Gusterson
Journal of Clinical Oncology 26 ( 18) 3006 -3014
266
2008
Understanding Adjuvant Chemotherapy for Breast Cancer
Aron Goldhirsch , Richard D. Gelber
The New England Journal of Medicine 330 ( 18) 1308 -1309
10
1994
Evaluation of the Quality of Life Associated with Zidovudine Treatment in Asymptomatic Human Immunodeficiency Virus Infection
William R. Lenderking , Richard D. Gelber , Deborah J. Cotton , Bernard F. Cole
The New England Journal of Medicine 330 ( 11) 738 -743
133
1994
Who Gets Chemotherapy for Metastatic Lung Cancer
Craig C. Earle , Laura N. Venditti , Peter J. Neumann , Richard D. Gelber
Chest 117 ( 5) 1239 -1246
273
2000
Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
Marco Colleoni , Anita Giobbie-Hurder , Meredith M. Regan , Beat Thürlimann
Journal of Clinical Oncology 29 ( 9) 1117 -1124
117
2011
Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
Marianne Ewertz , Kathryn P Gray , Meredith M Regan , Bent Ejlertsen
Journal of Clinical Oncology 30 ( 32) 3967 -3975
78
2012
Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).
Halle C. F. Moore , Joseph M. Unger , Kelly-Anne Phillips , Frances M. Boyle
Journal of Clinical Oncology 32 ( 15_suppl) LBA505 -LBA505
52
2014
Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.
Olivia Pagani , Meredith M Regan , Barbara Walley , Gini F Fleming
Journal of Clinical Oncology 32 ( 15_suppl) LBA1 -LBA1
14
2014
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
Martine J Piccart-Gebhart , Andrew Peter Holmes , Jose Baselga , Evandro De Azambuja
Journal of Clinical Oncology 32 502 -502
125
2014
Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Amy Louise Billett , Stephen E. Sallan , Alexa Carls , Richard D. Gelber
Cancer 70 ( 1) 201 -206
64
1992